PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan Noriomi MatsumuraMasaki Mandai PMDA Regulatory Update 29 March 2024 Pages: 493 - 494
Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay Tadayoshi HashimotoYoshiaki NakamuraTakayuki Yoshino JSCO Board of Directors Series Open access 29 March 2024 Pages: 495 - 511
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2 Yoshinori KikuchiHideaki ShimadaHiroyuki Takahashi Special Article 17 March 2024 Pages: 512 - 534
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology Tomoya MaedaYuho NajimaShingo Yano Special Article Open access 18 March 2024 Pages: 535 - 544
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022 Keita UchinoShingo TamuraYuji Miura Special Article 22 March 2024 Pages: 545 - 550
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022 Yukinori OzakiTakamichi YokoeToshimi Takano Special Article 25 March 2024 Pages: 551 - 558
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022 Shoji KimuraKeisuke ShigetaYuji Miura Special Article 28 March 2024 Pages: 559 - 563
Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry Ryoko RikitakeYu MizushimaAkira Kawai Cancer Statistics Open access 27 February 2024 Pages: 564 - 570
An approach for improvement of the accuracy of cancer gene panel testing Kiyomi ImotoHiroyuki YamamotoYu Sunakawa Original Article 12 March 2024 Pages: 571 - 581
Lymphatic drainage patterns of malignant skin tumors in the head and neck region: a single-center retrospective study Takuya NishioTaku MaedaToshihiko Hayashi Original Article 30 March 2024 Pages: 582 - 591
Sarcopenia is associated with leukopenia in urothelial carcinoma patients who receive tislelizumab combined with gemcitabine and cisplatin therapy Zhimin GaoYubin PangHailong Li Original Article Open access 22 March 2024 Pages: 592 - 601
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study Rikiya TaokaMasaki KamadaMikio Sugimoto Original Article 28 February 2024 Pages: 602 - 611
Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab Masaki HashimotoWataru FukuokayaTakahiro Kimura Original Article 02 March 2024 Pages: 612 - 619
MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial Han Byul KangSung Hwan KimJong Hoon Lee Original Article 26 March 2024 Pages: 620 - 628
Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial Motohiro MatsuiAtsushi MakimotoYuki Yuza Original Article 02 April 2024 Pages: 629 - 637
